TABLE 2.
Blood and cerebrospinal fluid findings and comorbid conditions in patients with inflammatory neuropathies and controls
| Parameter | GBS | CIDP | PDN | MMN | HC | HA | NIP | ALS | ||
|---|---|---|---|---|---|---|---|---|---|---|
| GBSa | GBSb | CIDPa | CIDPb | |||||||
| CSF cells (×106/L) | ||||||||||
| Mean (median) | 3.8 (2) | 4.5 (2.5) | 3.4 (2.5) | 3.4 (2.5) | 2.3 (2.4) | 1.6 (1.4) | 1.7 (2.3) | 1.9 (2) | 1.9 (2) | 2.2 (1.3) |
| Range | 0–23 | 0–22 | 0–22 | 1–9.3 | 0.6–4 | 1.1–3 | 0–2.5 | 0–4 | 0–5.1 | 0–20 |
| Q‐albumin (CSF/plasma) | ||||||||||
| Mean (median) | 19.9 (15.8) | 21.6 (14.7) | 11.2 (10.2) | 18.2 (13.6) | 12.1 (12) | 4.8 (3.8) | 4.7 (4.3) | 5.2 (5) | 6.9 (7) | 6.3 (6.2) |
| Range | 5–50.2 | 3.5–62.4 | 3.2–21.2 | 2.6–59.8 | 5.6–19.8 | 2–9.2 | 2.9–7.6 | 2.2–8.5 | 1.1–15 | 2–11.9 |
| OCB in CSF, N (%) | 0 (0) | 0 (0) | 0 (0) | 1 (8) | 1 (10) | 0 (0) | 0 (0) | 0 (0) | 1 (5) | 1 (3) |
| Paraprotein, N (%) | 0 (0) | 0 (0) | 9 (47)1 | 3 (23) 1 | 10 (100) 2 | 0 | NA | NA | NA | NA |
| MAG‐antibodies2, N (%) | NA | NA | 0 (0) | 0 (0) | 9 (90) | 0 (0) | NA | NA | NA | NA |
| Ganglioside antibodies in patients tested, N (%) | 2 of 103 (20) | NA | 1 of 84 (13) | 3 of 55 (60) | 3 of 46 (75) | 3 of 87 (38) | NA | NA | NA | NA |
| Previous infections8, N (%) | 13 (54) | 7 (41) | NA | NA | NA | NA | NA | NA | NA | NA |
| Comorbid diseases: | ||||||||||
| Autoimmune, infectious | 2 9 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Diabetes (type 2) | 4 | 3 | 0 | 0 | 0 | 1 | 0 | 2 | 5 | 1 |
| Other diseases 10 | 13 | 8 | 20 | 11 | 8 | 4 | 1 | 8 | 11 | 20 |
Note: 1IgG or IgA; 2IgM; 3IgG‐GQ1b ab; 4IgM‐GM1, IgM‐GD1b ab; 5IgM‐GM1, IgM‐GM2, IgM‐GD1b, IgM‐GQ1b ab; 6IgM‐GM1, IgM‐GM2, IgM‐GD1a, IgM‐GD1b, IgM‐GQ1b ab; 7IgM anti‐GM1; 8within 6 weeks prior to onset; 9psoriasis and hepatitis C; 10cardiovascular (hypertension, atrial fibrillation, arrhythmia, hyperlipidemia); airway (chronic obstructive pulmonary disease [COPD], asthma); endocrine (hypothyroidism); orthopaedic (arthrosis); neurological (migraine, restless legs syndrome, essential tremor); others (rosacea, osteoporosis, anemia, nephrolithiasis).
Abbreviations: a, pre‐treatment; ALS, amyotrophic lateral sclerosis; b, post‐treatment; CIDP, chronic inflammatory demyelinating polyneuropathy; CSF, cerebrospinal fluid; GBS, Guillain–Barré syndrome; HA, headaches; HC, healthy controls; MMN, multifocal motor neuropathy; NA, not applicable; NIP, non‐inflammatory polyneuropathy; OCB, oligoclonal bands; PDN, paraproteinaemic demyelinating neuropathy; Q‐albumin, ratio of albumin in CSF (mg/L)/plasma (g/L) × 10−3 (reference range: 15–29 years <6.0 × 10−3; 30–49 years <7.0 × 10−3; ≥50 years <9.0 × 10−3).